Advanced search

Filter By:

Journal Check one or more journals to show results from those journals only.

Choose more journals

Article type Check one or more article types to show results from those article types only.
Subject Check one or more subjects to show results from those subjects only.
Date Choose a date option to show results from those dates only.

Custom date range

Clear all filters
Sort by:
Showing 1–2 of 2 results
Advanced filters: Author: Gerrit-Jan Wolbink Clear advanced filters

  • The presence of anti-drug antibodies (ADA) can result in the loss of response to anti-TNF biologic agents in patients with rheumatoid arthritis. In this article, van Schouwenburg et al. outline the limitations of current assays for ADA detection and discuss how studying the immune responses caused by the different anti-TNF biologic agents could lead to strategies to help reduce or prevent the development of ADA.

    • Pauline A. van Schouwenburg
    • Theo Rispens
    • Gerrit Jan Wolbink
    Reviews
    Nature Reviews Rheumatology
    Volume: 9, P: 164-172

  • Strategies to reduce the immunogenicity that occurs following treatment with most biologic agents are a growing subject of investigation. A novel approach to induce tolerance to a therapeutic monoclonal antibody, alemtuzumab, has yielded promising results.

    • Charlotte L. M. Krieckaert
    • G. Margret Bartelds
    • Gerrit-Jan Wolbink
    News & Views
    Nature Reviews Rheumatology
    Volume: 6, P: 558-559